Predicted to enable DNA binding activity and DNA-binding transcription activator activity, RNA polymerase II-specific. Predicted to contribute to RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in positive regulation of transcription by RNA polymerase II. Predicted to act upstream of or within positive regulation of DNA-templated transcription. Part of CCAAT-binding activity factor complex. Orthologous to human NFYC (nuclear transcription factor Y subunit gamma); PARTICIPATES IN aldosterone signaling pathway; altered p53 signaling pathway; antigen processing and presentation pathway; INTERACTS WITH 17alpha-ethynylestradiol; 2,3,7,8-tetrachlorodibenzodioxine; 2,6-dinitrotoluene.
[Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of NFYC mRNA more ...
[Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of NFYC mRNA more ...
[Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of NFYC mRNA and [sodium arsenite co-treated with Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of NFYC mRNA
Methylnitronitrosoguanidine promotes the reaction [NFYC protein binds to RRM2 promoter] and Methylnitronitrosoguanidine promotes the reaction [NFYC protein results in increased expression of RRM2 mRNA]
[sodium arsenite co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of NFYC mRNA and [sodium arsenite co-treated with Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of NFYC mRNA